U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07083349) titled 'NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus' on July 16.
Brief Summary: This is an investigator-initiated, open-label, single-arm study to determine safety and preliminary efficacy of NK510 for the treatment of patients with refractory systemic lupus erythematosus (SLE) in China.
Study Start Date: Aug. 01
Study Type: INTERVENTIONAL
Condition:
Refractory Systemic Lupus Erythematosus
Intervention:
DRUG: NK510 : allogeneic genetic modified NK
NK510 is an allogeneic genetic modification of NK cell. NK510 will be administered at a dose of 4x10^7 NK/kg, 8x10^7 NK/kg and 1.2x10^8 NK/kg by a dose-escalation design ...